Condition
Group B Streptococcus (GBS) Disease
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
P 1 (2)
Trial Status
Completed2
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT06896526Not Yet Recruiting
Comprehensive Outcomes Monitoring for Peri- and Postnatal Invasive Group B Strep Sequelae (COMPPASS) Registry
NCT01053767Phase 1CompletedPrimary
A Study to Assess the Persistence of Two GBS Antibodies in Women Previously Immunized With a GBS Vaccine
NCT01052935Phase 1CompletedPrimary
A Study to Assess the Persistence of a GBS Antibody in Women Previously Immunized With a GBS Vaccine
Showing all 3 trials